A previously unreported Kazal-type serine protease inhibitor, serine protease inhibitor Kazal type 9 (SPINK9), was identified in human skin. SPINK9 expression was strong in palmar epidermis, but not detectable or very low in non palmoplantar skin. Analysis of a human cDNA panel showed intermediate expression in thymus, pancreas, liver, and brain, and low or undetectable expression in other tissues. Using kallikrein-related peptidases (KLKs) 5, 7, 8, and 14, thrombin, trypsin, and chymotrypsin, inhibition with recombinant SPINK9 was seen only for KLK5 using low molecular weight substrates, with an apparent K i of 65 nM. Also KLK5 degradation of fibrinogen was totally inhibited by SPINK9. Slight inhibition of KLK8 using fibrinogen substrate could be observed using high concentrations of SPINK9. Analyses by surface plasmon resonance showed heterogeneous binding to SPINK9 of KLK5 and KLK8, but no binding of KLK7 or KLK14. KLK5 has been suggested to play a central role in skin desquamation as an initiating activating enzyme in proteolytic cascades formed by KLKs. An apparently KLK5-specific inhibitor, such as SPINK9, may play a significant regulatory role in such cascades. We suggest a possible role for SPINK9 in the site-specific epidermal differentiation of palms and soles.
INTRODUCTION
The importance of serine protease inhibitors and, deductively, of a well-regulated activity of serine proteases in skin homeostasis was shown when the genetic background of the Comel-Netherton syndrome (OMIM 256500) was unraveled. A defective skin barrier is a major feature of this severe disease, leading to excessive loss of water and electrolytes in the newborn, and a scaly, inflamed, itchy skin, highly prone to infections. The disease is caused by loss-of-function mutations in the serine protease inhibitor Kazal type 5 (SPINK5) gene, encoding the multidomain serine protease inhibitor LEKTI (lymphoepithelial Kazal-type related inhibitor). The skin barrier deficiency is believed to be the result of the ensuing elevated activity of serine proteases in the epidermis, leading to an increased rate of degradation of intercellular cohesive structures in the superficial cornified layer, the stratum corneum (Mägert et al., 1999; Chavanas et al., 2000; Sprecher et al., 2001; Walley et al., 2001; Komatsu et al., 2002; Hachem et al., 2006) . Supporting evidence has been obtained in animal studies, including generation of SPINK5 À/À mice (that mimic the Netherton phenotype) and transgenic mice overexpressing epidermal serine proteases (Ny and Egelrud, 2004; Yang et al., 2004; Descargues et al., 2005) .
Epidermal serine proteases suggested to be responsible for the phenotypic skin changes seen in Comel-Netherton syndrome belong to the tissue kallikreins, also named kallikrein-related peptidases (KLKs) (Lundwall et al., 2006) . Human KLKs is a group consisting of 15 related members with genes located on a 450 kb segment on the short arm of chromosome 19 (Yousef et al., 1999; Harvey et al., 2000) . KLKs are expressed by a wide variety of tissues. During the past decade, there has been a lot of focus on potential roles of KLKs as tumor markers, in tumor progression, activation of protease-activated receptors, and activation/inactivation of biologically active peptides (Borgoño et al., 2004; Clements et al., 2004; Oikonomopoulou et al., 2006; Yamasaki et al., 2006; Stefansson et al., 2008) . In the skin, two proteases eventually identified as KLK5 (previously stratum corneum tryptic enzyme) and KLK7 (previously stratum corneum chymotryptic enzyme) have been suggested to be involved in skin homeostasis and desquamation (Hansson et al., 1994; Brattsand and Egelrud, 1999) . Also several other KLKs, among them KLKs 6, 8, 9, 11, 13, and 14 , are expressed by the epidermis (Komatsu et al., 2003) . As KLKs are produced as catalytically inactive zymogen precursors, which can be activated by proteolytic removal of their respective propeptide, it has been proposed that they may function as parts of proteolytic cascades, analogous to, for example, enzymes involved in blood coagulation or complement activation. In this respect, KLK5 has received special attention, as among the KLKs it appears to be the most multipotent activator of KLK precursors, including its own precursor by auto activation (Brattsand et al., 2005; Yoon et al., 2007) .
The presence of a set of proteases with different catalytic properties and substrate specificities in a tissue such as the stratum corneum suggests the presence in the tissue also of intricate regulatory mechanisms. These mechanisms may include zymogen activation, inactivation by degradation, and regulation by physical-chemical parameters, such as pH, water content, and ionic composition (Egelrud, 1993; Watkinson et al., 2001; Caubet et al., 2004; Brattsand et al., 2005; Deraison et al., 2007) . The presence of specific inhibitors may, as illustrated above, play a crucial role. In our efforts to understand the interplay between serine proteases and various inhibitors of these enzymes present in human stratum corneum, we identified a hitherto not described Kazal-type serine protease inhibitor. Here, we report on purification, recombinant production, and tissue expression of this new inhibitor, tentatively named ''SPINK9,'' encoded by the human gene SPINK9. We also studied its interactions and inhibitory properties with a set of proteases. Our results suggest a high degree of specificity of SPINK9 as regard its inhibitory profile as well as its tissue expression pattern.
RESULTS
By means of reversed-phase chromatography, fractions with inhibitory activity toward several serine proteases could be separated from fractions containing protease activity, as shown for KLK5 in Figure 1a . Results from analyses of inhibitory activity of each fraction toward individual enzymes, and from immunoblot analyses with antibodies to known inhibitors expected to be present in extracts of stratum corneum (results not shown), implied that the fractions contained an unidentified inhibitor. After further purification (see Materials and Methods), three bands could be visualized after separation on SDS-PAGE (see Figure 1b) . Using mass spectrometry, band no. I could be identified as being derived from keratin. Band II could not be identified, whereas band III was identified (expectation value e À12.51 , 6 out of 24 masses were matched and a sequence coverage of 50.6%) as the putative SPINK9 (alias LEKTI2, accession no. AY396740; NP_001035523; gene SPINK9, GeneID: 643394; chromosome 5q33.1). The identity could be further verified by conventional N-terminal amino-acid sequence analysis (Figure 2b ). There was a K/Q mismatch between purified and deduced protein; this was not further studied.
Recombinant SPINK9
Computer analysis of the amino-acid sequence deduced from cDNA (SignalP; www.expasy.org/tools/) predicted signal cleavage between amino acids 19 and 20 (FS-IE). Primer pairs were designed from the published cDNA sequence. PCR amplification of cDNA from HaCaT cells using the primer pair SPINK9F1-SPINK9R1 (see Figure 2c ), designed to yield a product encoding the entire protein, including the signal peptide, resulted in a fragment containing, in addition to open reading frames encoding the entire protein, the first intron downstream the open reading frame of the postulated Figure 1 . Characterization of proteins with KLK5-inhibiting activity in plantar stratum corneum and recombinant SPINK9. (a) An acetic acid extract of plantar stratum corneum was subjected to reversed-phase chromatography. Recombinant KLK5 was added to samples of each fraction, which were then analyzed for activity toward the substrate S-2288. Hundred percent activity corresponds to activity when fraction samples were substituted with 0.1% trifluoroacetic acid. The high activity seen in fraction nos. 17-23 is due to the activity of proteolytic enzymes present in the extract. KLK5-inhibiting activity was found in fraction nos. 9-15. The peak at mass-to-charge ratio (m/z) 7726.458 corresponds to monomeric SPINK9, whereas a mass-to-charge ratio of 15458.161 corresponds to SPINK9 in dimeric form.
www.jidonline.org 1657 signal peptide. This fragment could be used as template to amplify a cDNA encoding the postulated secreted protein, that is, the whole protein excluding the signal peptide, six amino-acid residues longer at the N-terminal end than the purified native protein (Figure 2a-c) .
Analysis by mass spectrometry of recombinant SPINK9 after enterokinase cleavage and subsequent purification showed a pure protein with the correct N terminus and a calculated molecular mass of 7731 Da (theoretical value 7726). A dimer form of the protein was also observed (see Figure 1e) . A comparison of recombinant SPINK9 with the corresponding native protein by SDS-PAGE and immunoblotting is shown in Figure 1c and d. As expected from amino-acid sequence analyses, the native protein, having six fewer N-terminal amino-acid residues, had a slightly smaller apparent molecular mass (Figures 1c, d and 2b) . 
Protein-protein interaction studies
To investigate possible interactions between SPINK9 and KLK5, KLK7, KLK8, and KLK14, surface plasmon resonance technology was used. KLK7 and KLK14 were found not to interact with SPINK9. In accordance with inhibition experiments (see below), KLK5 showed high affinity for SPINK9. KLK8 also showed affinity for SPINK9; however, this interaction was markedly weaker. When evaluating KLK5 and KLK8 interactions with SPINK9, a simple Langmuir 1:1 model was insufficient to describe the binding. Both interactions were characterized by heterogeneity, that is, two parallel binding reactions. KLK5 showed kinetic parameters, indicating one rapid and one slower association rate constant; Figure 3a ). From these values, two dissociation constants were calculated,
, and Figure 3b ). Figure 3c shows plotted steady-state values of binding of KLK5 and KLK8 to SPINK9. A double rectangular four parameter regression model was used to calculate
À8 M and 2.5 Â 10 À7 M, and
and 5.2 Â 10 À6 M for KLK5 and KLK8, respectively, confirming the difference in affinity for SPINK9 between the two enzymes, as well as the heterogeneity of the binding reactions.
Inhibition of serine proteases by SPINK9
Among the enzymes tested (bovine trypsin, bovine chymotrypsin, human thrombin, human KLK5, KLK7, KLK8, and KLK14), significant inhibition by recombinant SPINK9 could be shown only for KLK5. By determining EC50 at different enzyme concentrations, an apparent K i of around 65 nM at pH 8 could be estimated. Lowering the pH to 5.5 gave comparable results for K i and had no effect on specificity (data not shown). Control experiments performed with a recombinant protein corresponding to the native SPINK9 purified from epidermis (denoted as epSPINK9), that is, six amino acids shorter, showed similar results. Figure 4a and b shows results for the four KLKs with chromogenic peptide substrates, and Figure 4c shows results for the four KLKs with a casein substrate. The activity of KLK8 toward casein was too low to allow for testing of inhibitor activity.
As KLK8 showed essentially undetectable activity toward the casein substrate, a fibrinogen assay was used to further analyze the inhibitory activity of SPINK9. As can be seen in Figure 4d , KLK8 could degrade fibrinogen, but only at a very low rate as compared with KLK5. Also the degradation pattern differed. Whereas KLK5 preferentially degraded the achain, KLK8 appeared to be most efficient toward the bchain. Figure 4e shows that high concentrations of SPINK9 (7.5 mM) result in a slight reduction of the KLK8 degradation of fibrinogen, whereas at these inhibitor concentrations, fibrinogen degradation by KLK5 was completely abolished. Already at 55 nM SPINK9, significant inhibition of KLK5 could be observed (data not shown). No inhibition could be detected with KLK7 or KLK14 in this assay (data not shown). 1,000 2,000 3,000 4,000 5,000 0
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Expression studies
In contrast to extracts of palmoplantar stratum corneum, in which SPINK9 could be easily detected, it was not possible to show the presence of SPINK9 in extracts of nonpalmoplantar stratum corneum by immunoblotting (results not shown). This apparent selective expression of SPINK9 in palms and soles was supported by immunohistochemical analyses. Whereas LEKTI and KLK5 showed the expected labeling pattern, that is, of the stratum granulosum and stratum corneum in palmar as well as in gluteal skin, specific labeling with antibodies specific for SPINK9 was seen only in the upper layers of palmar skin ( Figure 5 ). Highly selective expression of SPINK9 by human tissues could be shown also at the mRNA level. Figure 6 shows results from reverse transcriptase PCR with a primer pair designed to allow amplification of cDNA from the last two exons. In Figure 6a , RNA from palmar and gluteal skin from three individuals was analyzed. Figure 6b shows results for palmar skin and a commercial cDNA panel. At low number (25) of PCR cycles, an expected amplification product (248 bp) was obtained only from palmar RNA. After 30 cycles this product could be detected also in thymus, pancreas, liver, and brain, and after 35 cycles in all tissues except leukocytes and one out of three samples of gluteal skin.
In addition to the expected 248 bp product, a larger product was seen at higher numbers of PCR cycles in the cDNA panel. Nucleotide sequencing revealed that it contained the last intron, in addition to exon derived sequences (expected 1,310 bp). The intron sequence contains several stop codons, so no obvious open reading frame that could lead to a functional protein could be detected when translating the sequence. As control experiments (DNase treatment of RNA prior to cDNA synthesis and exclusion of the RT step) cannot be performed on the MTC panel, it cannot be excluded that the larger products seen in Figure 6b is due to trace amounts of genomic DNA in the samples, although this has never been observed with any other transcripts amplified from the same template (Brattsand and Egelrud, 1999) . For HaCaT cells (see above) there was evidence of true intron retention (Galante et al., 2004) . Amplification from other templates, like lymphomas and ovarian cancer tumors, have in some cases given rise to the same 1,310 bp product. In those cases, control experiments could exclude genomic contamination (data not shown). It is well known that RNA splicing can differ in various organs and may be an important regulatory factor (Hughes, 2006) . The presence in the palmar skin of full-length, fully spliced mRNA could be confirmed with reverse transcriptase PCR using the primer pairs SPINK9F1-SPINK9as1 and subsequent nucleotide sequencing (results not shown). All analyzed clones (n ¼ 5 from different sources) confirmed the nucleotide sequence that had been deposited in the database.
DISCUSSION
We isolated from human plantar stratum corneum a hitherto not described Kazal-type serine protease inhibitor. By database searches, this inhibitor could be identified as SPINK9. The sequence of the corresponding mRNA, prepared from the skin, had been deposited in 2003 by Wu, Bartels, and Schroeder (http://www.ncbi.nlm.nih.gov/entrez/viewer. fcgi?val=AY396740.1), who suggested the tentative name ''lymphoepithelial Kazal-type-related inhibitor 2; LEKTI2.'' Searches for amino-acid sequence similarities (http://www.ncbi.nlm.nih.gov/blast/Blast.cgi) identified three highly homologous proteins; in Pan troglodytes (97% identity, 98% positives), Macaca mulatta (89% identity, 96 % positives), and in Equus caballus (69% identity, 79% positives). Known human Kazal-type serine protease inhibitors are listed in Table 1 . The corresponding amino-acid sequences with the reactive cleavage sites in bold italics (Laskowski and Kato, 1980) are shown in Figure 2d 
SPINK9
Comparable results were obtained using the PROSITE tool (http://expasy.org/tools/scanprosite/). The uncommon amino-acid sequence of the reactive site of SPINK9 may be reflected in the seemingly high selectivity as regards enzymes toward which the inhibitor is active. Of the seven enzymes we tested, among which four were KLKs present in skin, only KLK5 was significantly inhibited by SPINK9. It is tempting to speculate that this apparent specificity for KLK5 may have physiological relevance. KLKs are produced as inactive precursors that are converted to active enzymes by proteolytic modifications. They are believed to interact in proteolytic cascades in which certain KLKs serve as activators of others. In this respect, KLK5 has autocatalytic activity, and is the most omnipotent among the KLKs as regards ability to activate precursors of other KLKs. KLK5 is the only enzyme known so far that can activate KLK7, a protease responsible for a major part of the total proteolytic activity in the stratum corneum (Brattsand et al., 2005; Yoon et al., 2007) . KLK5 may thus play a key role as an initiating enzyme in KLK cascades, with special demands on regulation of its activity giving rise to the evolution of specific inhibitors, such as SPINK9.
Serine protease inhibitor Kazal type 9 appears to have high specificity with regard to also tissue expression. We found high expression only in epidermis from palms and soles. By immunohistochemistry, western blot (data not shown), as well as reverse transcriptase PCR, a marked difference in SPINK9 expression between the skin from palms and soles and the skin from other parts of the body was seen. These differences may reflect structural and functional differences between the two types of skin. Palmoplantar stratum corneum has a high resistance to mechanical trauma, reflected by a different pattern of corneodesmosomal degradation as compared with stratum corneum at other body sites. Studies on desmosomal proteins and desmosome frequency have shown that, with the exception of regions of interdigitation between corneocyte edges, desmosomes disappear in the lower stratum corneum of nonpalmoplantar epidermis, whereas they persist all the way up to the desquamating corneocytes in palmoplantar epidermis (Skerrow et al., 1989; Serre et al., 1991) . As desmosomes are responsible for the mechanical integrity of the stratum corneum, and desmosomal proteins are suggested substrates of KLKs in this tissue, and as KLK5 may be a key enzyme in the activation of other KLKs, it is possible that the expression of SPINK9 may be part of the epidermal differentiation program specific for palmoplantar skin. As revealed by PCR, the second highest expression of SPINK9, next to palmar skin, was seen in the thymus and pancreas. These findings imply a role for SPINK9 in immunology and may, in spite of very low expression seen in other epithelial organs, give a rational for the proposed name ''LEKTI2.'' As far as we know, there are no monogenetic skin d iseases preferentially affecting palms and soles for which the disease-causing mutations have been localized to the same chromosomal region as SPINK9 (chromosome 5q33.1). In spite of this, a role of SPINK9 in skin pathophysiology cannot be excluded. In this respect, diseases such as dyshidrotic eczema and pustulosis palmoplantaris may be interesting candidates for further studies. Interestingly, patients suffering from Netherton syndrome often show no symptoms in their palms and soles, suggesting the possibility that perhaps partially redundant SPINK9 in palmoplantar skin may ''rescue'' SPINK5 mutations in this disease (Smith et al., 1995) .
Surface plasmon resonance (SPR) analyses showed significant binding of KLK8 to SPINK9, although with lower affinity than for KLK5. Using low molecular weight substrates, we could not show inhibition by SPINK9 of KLK8, not even at high concentrations of the inhibitor. Using the high molecular weight substrate fibrinogen, we could show a slight inhibition by SPINK9 using high, probably nonphysiological concentrations of the inhibitor (Figure 4d ). Even at the high concentrations used, not all KLK8 fibrinogen degradation activity could be inhibited. This is compatible with a model, where SPINK9 binds to a site different from the catalytic site of KLK8 and sterically inhibits interactions with large substrates but not with low molecular weight substrates. M Brattsand et al.
The fact that SPINK9 was an efficient inhibitor of KLK5 with low molecular as well as high molecular weight substrates suggests that SPINK9 is indeed interacting with KLK5 at or very close to the active site of the enzyme.
The SPR results showed heterogeneity in binding of SPINK9 to KLK5 and KLK8. For both enzymes, a best fit of observed data was obtained assuming two separate binding reactions. This suggests other types of interactions than what would be expected according to the proposed standard mechanism of interaction between Kazal-type inhibitors and serine proteases (Laskowski and Kato, 1980) . Hypothetically, KLK5-for which catalytic activity could be effectively inhibited by SPINK9-has one high affinity binding site for SPINK9 according to the standard mechanism, and one binding site with lower affinity. Correspondingly, KLK8 may bind SPINK9 at sites not involved in catalysis, as discussed above. An alternative explanation is that our preparation of recombinant SPINK9 is heterogeneous. As we produced recombinant SPINK9 in bacteria, we cannot rule out misfolding of part of the preparation used in the experiments. As inhibitor concentrations were calculated from protein concentration in our kinetic analyses, we may have underestimated the inhibitory efficiency of SPINK9 toward KLK5.
Although the observed K i for inhibition by SPINK9 of KLK5 may be low enough to be physiologically relevant, it is high as compared with corresponding values for the most efficient LEKTI peptides (Schechter et al., 2005; Deraison et al., 2007) . As we did not investigate the effect of SPINK9 on all serine proteases known to be produced by the epidermis, we cannot exclude that other proteases are ''the true targets'' for this inhibitor. It is also possible that SPINK9 has other physiological functions, as it was recently reported that SPINK9 has antimicrobial activity (Wu et al., 2008) . Novel protease targets as well as physiological functions of SPINK9 in skin and other tissues will be the scope of further studies.
MATERIALS AND METHODS

Recombinant enzymes
Recombinant KLK5 was produced as a fusion protein, with the propeptide of KLK7 mutated with an enterokinase site in the end, fused with the catalytically active part of KLK5. For further details, see Supplementary Materials and Methods. Production of recombinant KLK7, KLK8, and KLK14 has been described elsewhere (Brattsand et al., 2005; Stefansson et al., 2006 Stefansson et al., , 2008 . Trypsin was purchased from Boehringer Mannheim (Mannheim, Germany). Active site titration of proteases was carried out as described (Brattsand et al., 2005) .
Protein purification and characterization
Proteins were extracted from dry plantar stratum corneum (Egelrud, 1993) in acetic acid as described (Stefansson et al., 2006) and subjected to reversed-phase chromatography (RPC) (Brattsand and Egelrud, 1999) . Fractions were screened for inhibitory activity toward KLK5 as described below and in the legend to Figure 1 (Brattsand et al., 2005) . Fractions showing inhibitory activity (nos. 9-15, see Figure 1a ) from four different preparations were pooled and subjected to a second run of RPC. The fraction showing highest inhibitory activity against KLK5 was concentrated, further fractionated by gel exclusion chromatography (Stefansson et al., 2006) , and submitted to a third run of RPC. For identification of purified proteins by mass spectrometry, samples of inhibitor-containing fractions from the final RPC were evaporated, dissolved in reducing sample buffer, and separated on SDS-PAGE. Gel pieces with protein bands were cut out, trypsinated, and analyzed using a matrix-associated laser desorption ionization-time of flight instrument (MALDI micro MX, Waters, Milford, MA). The masses of the fragments resulting from trypsin digestion are determined using mass spectrometry. Experimentally found patterns of fragment sizes are then compared with information in databases, and proteins can thereby be identified. Protein digestion and mass spectrometry were performed at the Swegene proteomics resource center in Lund, Sweden (http:// www.lth.se/sciblu/services/proteomics). For further details, see Supplementary Materials and Methods.
Amino-acid sequence analysis of proteins separated by SDS-PAGE and transferred to polyvinylidene difluoride filters was performed as previously described (Matsudaira, 1987; Brattsand and Egelrud, 1999) .
Cloning, purification, and characterization of recombinant SPINK9 and epSPINK9 cDNA was produced from total RNA prepared from HaCaT keratinocyte cell line as described (Brattsand and Egelrud, 1999) using SuperScript III reversed transcriptase as recommended by the vendor (Invitrogen, Carlsbad, CA). The cDNA was amplified in two steps as described in Supplementary Materials and Methods and inserted into the pET-32 EK/LIC vector according to the manual (Novagen, Madison, WI). For protein production, the resulting plasmids were expressed in E. coli OriB(DE3)pLysS as recommended (Novagen). Recombinant protein was purified on a HisTrap HP column (GE Healthcare, Freiburg, Germany). Tag sequences were cleaved off using recombinant enterokinase (Novagen), and the recombinant SPINK9/epSPINK9 was then purified by RPC, following the same protocol as above. The purity of the recombinant protein was analyzed by mass spectrometry performed at the IMBIM proteomic resource center (Uppsala, Sweden; http://www.imbim. uu.se/resource/proteomics.html; see Figure 1e ).
Inhibitor concentration was determined by absorbance measurements at 280 nm using a NanoDrop spectrophotometer (Thermo Scientific, Waltham, MA). The extinction coefficient (E1%), based on amino-acid composition, was set to 6.00 for SPINK9 and 6.60 for epSPINK9, and the molecular weight used for calculations was 7731 and 7064 Da, respectively.
Surface plasmon resonance
Surface plasmon resonance is a technique and optical phenomenon that is used to detect and quantify interactions between biomolecules monitored in real time. To perform an analysis, one interactant (SPINK9 in this case) is immobilized on the matrix of a sensor ship. Sample containing the other interactant (in our experiments, the enzymes) is injected over the surface in a precisely controlled flow. Binding events causes changes in the SPR signal and is monitored as a sensorgram that expresses the resonance units as the function of time. Protein-protein interaction experiments were performed on a Biacore 2000 (Biacore, Uppsala, Sweden) using CM5 sensor chips and HBS-EP buffer (10 mM HEPES, 0.15 M NaCl, 3 mM EDTA, 0.05% www.jidonline.org 1663 M Brattsand et al. 
Inhibition experiments
In inhibition experiments, enzyme, inhibitor, and buffer was mixed and allowed to reach equilibrium for 15 minutes. Then chromogenic substrate was added and initial cleavage rates were measured. For further details, see figure legends and Supplementary Materials and Methods.
To study the inhibition using macromolecular substrates, casein and fibrinogen were tested. The EnzChek Protease Assay Kit (E6638, Molecular Probes, Eugene, OR) was used essentially according to the manufacturer's instructions. Fibrinogen (Haemochrom Diagnostica, Mö lndal, Sweden) was incubated with enzyme ± SPINK9 inhibitor at 37 1C for different time periods. The resulting fibrinogen fragments were then separated on 12% SDS-PAGE and visualized using PageBlue (Fermentas). For further details, see figure legends and Supplementary Materials and Methods.
Tissue preparation
Four-millimeter punch biopsies were taken from the skin of the upper gluteal region or from palms of healthy human volunteers (two males and two females aged 26-59 years) after written informed consent and with the approval of the Human Research Ethics Committee (Umeå University, reg. no. 00-004) and according to the Declaration of Helsinki principles. Skin biopsies were either fixed in buffered formaldehyde and embedded in paraffin according to routine protocols or used for the preparation of total RNA using TRIzol according to the manual (Invitrogen).
Immunohistochemistry
Serine protease inhibitor Kazal type 9-specific rabbit polyclonal antibodies were raised by immunizing with a mixture of the synthetic peptides and then reimmunizing the same rabbit with nontagged, native recombinant SPINK9. Antibodies (Ce-SPINK9) were affinity-purified on a column with recombinant SPINK9 still containing the tag sequences. Adsorption experiments using recombinant protein abolished the signal observed (data not shown). Preparation and characterization of KLK5-specific antiserum Pe-C1 has been described elsewhere (Ekholm et al., 2000) . LEKTI antibodies were purchased from Zymed laboratories (San Francisco, CA) (mouse anti-LEKTI clone 1C11G6). Secondary antibodies were biotinylated horse anti-mouse or goat anti-rabbit (Vector Laboratories, Burlingame, CA). Immunohistochemistry was performed as described before (Stefansson et al., 2006) using primary antibody concentration 1 mg ml À1 . For visualization, the avidin-biotin complex ABC method (Vector Laboratories) was used with the chromogenic substrate 3-amino-9-etylcarbazol (Dako Cytomation, Solna, Sweden).
Expression of SPINK9 cDNA in human tissues
Total RNA was extracted as described above, and cDNA was synthesized after DNase treatment using DNase I and SuperScript II (Invitrogen) as recommended. PCR was performed on cDNA prepared from skin biopsies as well as MTC panels I and II purchased from CLONTECH (Mountain View, CA) using the Advantage 2 Polymerase Mix as recommended. The number of PCR cycles run is specified in Figures 6a and b . For further details, see Supplementary Materials and Methods.
